



Original research Articles

Review of Villi Chorialis Necrosis in Preeclampsia Based on Lactate Dehydrogenase and Vitamin D Levels

Laksmi Maharani^{1*}, Nany Hairunisa², Lily Marliany Surjadi¹

1. Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Trisakti Jakarta, Indonesia.

2. Department of Occupational Medicine, Faculty of Medicine, Universitas Trisakti Jakarta, Indonesia

Abstract:- Preeclampsia is a cause of maternal-perinatal morbidity and mortality and ranks first as a cause of maternal death in Indonesia. Although the leading cause remains unclear, abnormal placentation is believed to be the underlying cause of endothelial dysregulation, leading to vasoconstriction and increased vascular permeability, which in turn contribute to the development of preeclampsia. Vitamin D, as an antioxidant, can help maintain the trophoblast invasion process and increase anti-inflammatory cytokines, thereby reducing the formation of necrotic debris and maternal clinical deterioration.

Keywords: preeclampsia; syncytial nuclear aggregates (SNA); villous necrosis.

Copyright : © 2025 The Authors. Published by Publisher. This is an open access article under the CC BY-NC-ND license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Supplementary information The online version of this article (<https://doi.org/xx.xxx/xxx.xx>) contains supplementary material, which is available to authorized users.

Corresponding Author: Laksmi Maharani¹, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Trisakti Jakarta, Indonesia.

BACKGROUND:

Preeclampsia is known to be one of the causes of maternal-perinatal mortality and morbidity, with an estimated 2-8% of women worldwide suffering from it.¹ Based on 2016 data from the Health Research and Development Agency (Litbangkes), preeclampsia ranks first in maternal mortality in Indonesia, accounting for 33%, followed by bleeding and infection.² The high incidence of preterm labor in preeclampsia also results in complications in newborns, such as intraventricular hemorrhage, necrotizing enterocolitis, and bronchopulmonary dysplasia, which can affect growth, often resulting in a birth weight below the 10th percentile in childhood.³

The diagnosis of preeclampsia, according to the International Society for the Study of Hypertension in Pregnancy (ISSHP), is clinically determined by hypertension (blood pressure $\geq 140/90$ mmHg on two measurements 4 hours apart) occurring at 20 weeks of gestation and proteinuria (≥ 300 mg/24 hours, protein/creatinine ratio ≥ 0.3 /day, or 1+ in urine protein dipstick), or hypertension without proteinuria but with systemic abnormalities in the form of thrombocytopenia ($< 100,000/\mu\text{L}$), renal insufficiency (creatinine > 1.1 mg/dL or an increase in creatinine 2 times the normal value in the absence of previous kidney disorders), increased liver enzymes, pulmonary edema and central nervous or visual disturbances.⁴

Several conditions have been identified as risk factors for preeclampsia, such as primigravida, pregnant women over 40 years of age, and obesity. Lack of exposure to sperm and semen, and pregnancies with oocyte or embryo donors are also considered contributing factors. A family history of preeclampsia, especially on the mother's side, and a history of preeclampsia in a previous pregnancy increase the risk of recurrent preeclampsia. Similarly, multiple pregnancies, diabetes mellitus, systemic lupus erythematosus (SLE), chronic hypertension, and kidney disorders are also pathologies that increase the incidence of preeclampsia.^{4,5}

Pathogenesis of Preeclampsia

Preeclampsia is a maternal syndrome in which the placenta is confirmed to be the organ most closely related to the event.⁶ Although the leading cause is still not fully understood, the occurrence of abnormal placentation is the cause of endothelial dysregulation resulting in vasoconstriction and increased vascular permeability, resulting in a varied clinical picture of preeclampsia.^{6,7} Decreased uteroplacental blood flow due to abnormal placentation causes placental stress, triggering the release of necrotic trophoblast debris originating from the syncytiotrophoblast and causing a maternal systemic inflammatory response.^{6,8} This is because the remodeling process of the spiral artery does not run perfectly. Cytotrophoblast invasion only reaches the decidua area, so that the myometrium remains narrowed and produces high-pressure blood flow that causes damage to the placental villi.⁸⁻¹⁰ Meanwhile, in normal placentation, cytotrophoblast invasion reaches the endothelial layer of the spiral artery's smooth muscle, forming blood vessels with a larger capacity, which allows maternal blood flow to the intervillous space, resulting in adequate placental perfusion for fetal growth.^{9,10}




Figure 1. Abnormal placenta in preeclampsia.⁹

Syncytial nuclear aggregates (SNA)/syncytial knots

Many mechanisms contribute to the pathogenesis of preeclampsia, where these mechanisms are interrelated and provide a synergistic effect causing the clinical symptoms of this disease. Placental factors, in the form of trophoblast debris, triggering the dysfunction or activation of maternal endothelial cells, have become a widely studied pathogenesis.^{11,12} Trophoblast debris originates from the syncytiotrophoblast layer, which is in direct contact with maternal blood and exhibits various shapes and sizes, ranging from the largest structure, multinuclear syncytial nuclear aggregates (SNA), to mononuclear structures, microparticles, and nanoparticles, which can enter the maternal bloodstream.^{13,14} In normal pregnancy, SNA is formed as a result of the apoptosis process. Phagocytosis of apoptotic SNA by maternal immune cells produces a tolerant immune response to the placenta/fetus and prevents endothelial cell activation.

The absence of a rejection response from the maternal immune system proves that in normal pregnancy, there is no excessive inflammatory response.¹¹ While phagocytosis of necrotic trophoblast debris causes an inflammatory response, such as that which occurs in preeclampsia,^{14,15} where syncytiotrophoblast dysfunction due to malperfusion of uteroplacental flow in early pregnancy gives a vascular inflammatory reaction that is stronger than in a normal placenta.¹⁶




Figure 2. Trophoblast material enters the maternal circulation.¹³

Inflammation and hypoxia in the placenta lead to microscopic structural changes, accompanied by an increase in the number of SNA formations. Complicated pregnancies also show SNA formation earlier than normal pregnancies.¹⁷ In preeclampsia, although SNA formations attached to the villi appear more numerous, syncytial bridges, the clusters of SNAs connecting two villi, appear to be reduced.^{18,17,18} Nearly 4 decades ago, Jones and Fox discovered the appearance of syncytial bridges, which at that time were stated to possibly have a mechanical function to maintain placental stability¹⁹ and maintain adequate oxygen exposure to prevent the formation of reactive oxygen species that exacerbate cell necrosis.¹⁸

Effect of Lactate Dehydrogenase (LDH)

LDH is an intracellular enzyme found in living cells. Its activity increases in pathological conditions, making it frequently used as an indicator of cell damage.^{20,21} Preeclampsia is associated with necrotic cell death due to systemic maternal endothelial damage. Morphologically, necrotic cells appear swollen and eventually rupture, releasing plasma and intracellular components. The enzyme's location in the cytoplasm results in high serum LDH levels as the number of ruptured cells increases.²⁰ In preeclampsia, increased LDH concentrations are associated with increased blood pressure and more severe complications for both mother and baby.²² Increased LDH is also directly proportional to increased TNF- α , a pro-inflammatory cytokine, and increased evidence of villous necrosis.^{23,24} Furthermore, hypoxia in placental tissue indicates extensive necrosis, despite the presence of increased trophoblasts in some parts of the villi, which maintains the balance of cell formation.²⁴

The role and influence of vitamin D

Vitamin D deficiency is a public health problem. Prevalence in Asian countries ranges from 14 to 59%, with a figure of 25% in Jakarta, where the rate is particularly high, reaching 99.6%.^{25,26} It is known that many factors contribute to the occurrence of preeclampsia, including maternal disease factors, angiogenesis factors, endothelial dysfunction, and the formation of necrotic trophoblast debris, as well as the activation of pro-inflammatory factors that lead to placental damage.²⁷

Background malnutrition has also been stated as a trigger for this occurrence. The active form of vitamin D, 1,25-dihydroxyvitamin D₃, functions as a steroid hormone that regulates gene transcription and cellular function, and is associated with placental implantation and trophoblast invasion. It plays a role in cell proliferation and the angiogenesis process. This can occur because the placenta, being one of the organs outside the kidney, can synthesize the active form of vitamin D through the activity of 1 α -hydroxylase in the trophoblast and decidua.^{28,29} Research on the role of 1,25-dihydroxyvitamin D₃ in cell proliferation and repair outside bone cell metabolism has been widely conducted.²⁹ One of them is the placenta that can respond to vitamin D because it has a vitamin D receptor (VDR), so that it can function to help the production of anti-inflammatory cytokines in the trophoblast and decidua, and support the process of placental implantation.²⁸ The occurrence of preeclampsia, which is closely related to abnormal implantation, requires adequate nutrition, one of which is vitamin D, to maintain the process of trophoblast invasion and increase anti-inflammatory cytokines, so that it can reduce the formation of necrotic debris and maternal clinical deterioration.^{30,31}

Vitamin D during pregnancy plays a role in maintaining and enhancing the appropriate maternal immune response by preventing the release of antiangiogenic substances into the bloodstream. On the other hand, vitamin D is also thought to increase the production of angiogenic substances in endothelial progenitor cells by increasing the expression of vascular endothelial growth factor VEGF and the activity of pro-matrix metalloproteinase (pro-MMP2).³⁰ Research has also found that vitamin D has a potential immunosuppressive effect, which plays a role in placental development. Vitamin D deficiency will increase the inflammatory process in the placenta. This is proven by research that found that preeclampsia sufferers have an average vitamin D level 14% lower than that of normal pregnant women.³¹

The numerous functions of vitamin D, particularly its immunomodulatory properties and beneficial effects on angiogenesis, have led to its potential role in preventing preeclampsia. However, several randomized studies have shown that vitamin D supplementation is ineffective in preventing preeclampsia. One such study by Mirzakhani et al. showed that vitamin D supplementation initiated at 10-18 weeks of gestation was ineffective in reducing the incidence of preeclampsia. However, vitamin D levels of 30 ng/mL or higher at 32-38 weeks of gestation were associated with a reduced risk of preeclampsia.³²⁻³⁴

CONCLUSION AND RECOMMENDATION :

Preeclampsia, a cause of maternal morbidity and mortality whose cause remains unknown, provides ample scope for discussion to clarify the pathological processes involved. Trophoblastic debris, a result of the inflammatory process caused by syncytiotrophoblast dysfunction, leads to uteroplacental blood flow malperfusion and exacerbates the maternal vascular inflammatory response. In preeclampsia, although SNA formation in the villi appears more numerous, syncytial bridges, as clusters of SNA connecting two villi, appear to be reduced. Further research is needed to determine whether the presence of syncytial bridges indeed functions as a mechanism for maintaining placental stability. Furthermore, vitamin D, a nutrient that plays a role in placentation and increases anti-inflammatory cytokines, needs further investigation to understand the mechanisms by which this vitamin supplementation can reduce necrotic debris formation and prevent maternal clinical deterioration.

References:

1. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. *Obstet Gynecol* [Internet]. 2020 Jun 1 [cited 2022 Sep 23];135(6):e237–60. Available from: https://journals.lww.com/greenjournal/Fulltext/2020/06000/Gestational_Hypertension_and_Preeclampsia_ACOG.46.aspx
2. Peringatan Hari Preeklamsia Sedunia 2021 [Internet]. [cited 2022 Sep 23]. Available from: <https://promkes.kemkes.go.id/peringatan-hari-preeklamsia-sedunia-2021>
3. Tousty P, Fraszczyk-Tousty M, Ksel-Hryciów J, Łoniewska B, Tousty J, Dzidek S, et al. Adverse Neonatal Outcome of Pregnancies Complicated by Preeclampsia. 2022; Available from: <https://doi.org/10.3390/biomedicines10082048>
4. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Hypertension*. 2018;72(1):24–43. Available from: <https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.117.10803>
5. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. *Integr Blood Press Control* [Internet]. 2015 Mar 3 [cited 2022 Sep 23];8:7. Available from: </pmc/articles/PMC4354613/>
6. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. *BMJ* [Internet]. 2019 Jul 15 [cited 2022 Sep 23];366. Available from: <https://www.bmj.com/content/366/bmj.l2381>
7. Martínez-Martínez MM, Fernández-Travieso J, Gómez Muñoz N, Varela Mezquita B, Almarcha-Menargues ML, Miralles Martínez A. Cerebral hemodynamics and vasoconstriction in preeclampsia: From diagnosis to resolution. *Pregnancy Hypertens*. 2021 Dec 1;26:42–7. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S2210778921005092>
8. Rana S, Lemoine E, Granger JP, Karumanchi SA. Compendium on the Pathophysiology and Treatment of Hypertension. 2019;1094–112. Available from: <https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.118.313276>

9. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of anti-angiogenic factors and implications for later cardiovascular disease. *Circulation* [Internet]. 2011 Jun 6 [cited 2022 Sep 23];123(24):2856–69. Available from: [/pmc/articles/PMC3148781/](https://pubmed.ncbi.nlm.nih.gov/23485144/)
10. Schoots MH, Gordijn SJ, Scherjon SA, van Goor H, Hillebrands JL. Oxidative stress in placental pathology. *Placenta* [Internet]. 2018;69:153–61. Available from: <https://doi.org/10.1016/j.placenta.2018.03.003>
11. Lau SY, Barrett CJ, Guild SJ, Chamley LW. Necrotic trophoblast debris increases blood pressure during pregnancy. *J Reprod Immunol*. 2013 Apr;97(2):175–82. Available from: <https://pubmed.ncbi.nlm.nih.gov/23485144/>
12. Wei J, Blenkiron C, Tsai P, James JL, Chen Q, Stone PR, et al. Placental trophoblast debris mediated fetomaternal signalling via small RNA delivery: implications for preeclampsia. Available from: www.nature.com/scientificreports/
13. Askelund KJ, Chamley LW. Trophoblast deportation part I: Review of the evidence demonstrating trophoblast shedding and deportation during human pregnancy. *Placenta*. 2011 Oct 1;32(10):716–23. Available from: doi: 10.1016/j.placenta.2011.07.081
14. Chamley LW, Chen Q, Ding J, Stone PR, Abumaree M. Trophoblast deportation: Just a waste disposal system or antigen sharing? *J Reprod Immunol*. 2011 Mar;88(2):99–105. Available from: <https://pubmed.ncbi.nlm.nih.gov/21334749/>
15. Wei J, Lau SY, Blenkiron C, Chen Q, James JL, Kleffmann T, et al. Trophoblastic debris modifies endothelial cell transcriptome in vitro: a mechanism by which fetal cells might control maternal responses to pregnancy. 2016; Available from: www.nature.com/scientificreports
16. Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. *Am J Obstet Gynecol*. 2015 Oct 1;213(4):S9.e1-S9.e4. Available from: <https://pubmed.ncbi.nlm.nih.gov/26428507/>
17. Calvert SJ, Jones CJP, Sibley CP, Aplin JD, Heazell AEP. Analysis of syncytial nuclear aggregates in preeclampsia shows increased sectioning artefacts and decreased inter-villous bridges compared to healthy placentas. *Placenta*. 2013 Dec 1;34(12):1251–4. Available from; <https://pubmed.ncbi.nlm.nih.gov/24172869/>
18. Heazell AEP, Moll SJ, Jones CJP, Baker PN, Crocker IP. Formation of Syncytial Knots is Increased by Hyperoxia, Hypoxia and Reactive Oxygen Species. *Placenta*. 2007 Apr 1;28(SUPPL.):S33–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/17140657/>
19. Jones CJP, Fox H. Syncytial knots and intervillous bridges in the human placenta: an ultrastructural study. Vol. 124, *J. Anat*. 1977. Available from: <https://europepmc.org/article/pmc/pmc1234832>
20. Chan FKM, Moriwaki K, De Rosa MJ. Detection of necrosis by release of lactate dehydrogenase activity. *Methods Mol Biol* [Internet]. 2013 [cited 2022 Sep 24];979:65–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/23397389/>
21. Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the Lactate Dehydrogenase Assay. *Cold Spring Harb Protoc* [Internet]. 2018 Jun 1 [cited 2022 Sep 24];2018(6):465–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/29858337/>

22. Gupta A, Bhandari N, Kharb S, Chauhan M. Lactate dehydrogenase levels in preeclampsia and its correlation with maternal and perinatal outcome. *Int J Reprod Contraception, Obstet Gynecol* [Internet]. 2019 Apr 1 [cited 2022 Sep 24];8(4):1505–11. Available from: <https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=23201770&v=2.1&it=r&id=GALE%7CA587366451&sid=googleScholar&linkaccess=fulltext>
23. Fakhr Y, Koshti S, Habibyan YB, Webster K, Hemmings DG. Tumor Necrosis Factor- α Induces a Preeclamptic-like Phenotype in Placental Villi via Sphingosine Kinase 1 Activation. *Int J Mol Sci* [Internet]. 2022 Apr 1 [cited 2022 Sep 24];23(7). Available from: [/pmc/articles/PMC8998215/](https://pubmed.ncbi.nlm.nih.gov/39898215/)
24. Crocker IP, Tansinda DM, Jones CJP, Baker PN. The Influence of Oxygen and Tumor Necrosis Factor- α on the Cellular Kinetics of Term Placental Villous Explants in Culture. *PLoS One* [Internet]. 2016 Jun 26 [cited 2022 Sep 24];11(6):e0161204. Available from: <https://doi.org/10.1371/journal.pone.0161204>
25. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? *J Steroid Biochem Mol Biol* [Internet]. 2014 [cited 2022 Sep 24];144(PART A):138. Available from: [/pmc/articles/PMC4018438/](https://pubmed.ncbi.nlm.nih.gov/24418438/)
26. Wibowo N, Bardosono S, Irwinda R, Syafitri I, Putri AS, Prameswari N. Assessment of the nutrient intake and micronutrient status in the first trimester of pregnant women in Jakarta. *Med J Indones*. 2017;26(2):109–15. Available from: <https://mji.ui.ac.id/journal/index.php/mji/article/view/1617>
27. Bakacak M, Serin S, Ercan O, Köstü B, Avci F, Kılınc M, et al. Comparison of Vitamin D levels in cases with preeclampsia, eclampsia and healthy pregnant women. *Int J Clin Exp Med* [Internet]. 2015 Sep 30 [cited 2022 Sep 24];8(9):16280. Available from: [/pmc/articles/PMC4659033/](https://pubmed.ncbi.nlm.nih.gov/264659033/)
28. Arora CP, Hobel CJ. Vitamin D - A novel role in pregnancy. *Biopolym Cell*. 2010;26(2):97–104. Available from: <https://biopolymers.org.ua/content/26/2/097/>
29. Ferreira De Almeida L, Coimbra TM. Vitamin D Actions on Cell Differentiation, Proliferation and Inflammation. *Int J Complement Altern Med* [Internet]. 2017 Apr 28 [cited 2022 Sep 24];Volume 6(Issue 5):1–6. Available from: <https://medcraveonline.com/IJCAM/IJCAM-06-00201.php>
30. Purswani JM, Gala P, Dwarkanath P, Larkin HM, Kurpad A, Mehta S. The role of vitamin D in pre-eclampsia: A systematic review. *BMC Pregnancy Childbirth* [Internet]. 2017 Jul 15 [cited 2022 Sep 25];17(1):1–15. Available from: <https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-017-1408-3>
31. Mirzakhani H, Litonjua AA, McElrath TF, O'Connor G, Lee-Parritz A, Iverson R, Macones G, Strunk RC, et al. Early pregnancy vitamin D status and risk of preeclampsia. *J Clin Invest*. 2016 Dec 1;126(12):4702–4715. doi: 10.1172/JCI89031. Epub 2016 Nov 14. PMID: 27841759; PMCID: PMC5127689.
32. Smith TA, Kirkpatrick DR, Kovilam O, Agrawal DK. Immunomodulatory role of vitamin D in the pathogenesis of preeclampsia. *Expert Rev Clin Immunol*. 2015;11(9):1055–63. doi: 10.1586/1744666X.2015.1056780. Epub 2015 Jun 22. PMID: 26098965; PMCID: PMC4829935.
33. Poniedziałek-Czajkowska E, Mierzyński R. Could Vitamin D Be Effective in Prevention of Preeclampsia? *Nutrients*. 2021 Oct 28;13(11):3854. doi: 10.3390/nu13113854. PMID: 34836111; PMCID: PMC8621759.
34. Ganguly A, Tamblyn JA, Finn-Sell S, Chan SY, Westwood M, Gupta J, et al. Vitamin D, the placenta and early pregnancy: effects on trophoblast function. *J Endocrinol* [Internet]. 2018 Feb 1 [cited 2022 Sep 24];196(2):R1–R12. Available from: <https://pubmed.ncbi.nlm.nih.gov/29618438/>

